You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunotherapy,%20A2aR,%20PDR001,%20NIR178,%20NSCLC,%20solid%20tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumors Trial in Worldwide (KAZ954, PDR001, NIR178)

Recruiting
  • Solid Tumors
  • Los Angeles, California
  • +12 more
Dec 23, 2022

NSCLC (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in Worldwide (NZV930, PDR001,

Terminated
  • Non-small Cell Lung Cancer (NSCLC)
  • +6 more
  • NZV930
  • +2 more
  • Tampa, Florida
  • +9 more
Nov 2, 2022

NSCLC, Ovarian Cancer, Melanoma Trial in Worldwide (LXH254, PDR001)

Terminated
  • NSCLC
  • +3 more
  • Boston, Massachusetts
  • +17 more
Dec 20, 2022

Advanced Malignancies Trial in Worldwide (MBG453, PDR001, Decitabine)

Terminated
  • Advanced Malignancies
  • Baltimore, Maryland
  • +13 more
Sep 20, 2022

Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer Trial in Worldwide (PDR001)

Completed
Has Results
  • Melanoma
  • +4 more
  • PDR001
  • Baltimore, Maryland
  • +40 more
Aug 2, 2022

NSCLC (NSCLC) Trial in Tampa (PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg)

Completed
  • Non-small Cell Lung Cancer (NSCLC)
  • PBF-509_80 mg
  • +8 more
  • Tampa, Florida
    H.Lee Moffitt Cancer center
Jan 3, 2022

Renal Cell Carcinoma, Melanoma, Solid Tumor Trial in Pittsburgh (Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 +

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Phase Ib ARRY-614 + nivolumab
  • +4 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jan 9, 2022

Advanced Solid Tumors Trial in Worldwide (LAG525, PDR001)

Completed
Has Results
  • Advanced Solid Tumors
  • New York, New York
  • +23 more
Jan 17, 2022

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

NSCLC Trial in Washington, Hackensack, Neptune (Nivolumab, Ipilimumab, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Washington, District of Columbia
  • +2 more
Jan 27, 2023

Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma Trial in Worldwide (MCS110, PDR001)

Completed
Has Results
  • Triple Negative Breast Cancer
  • +3 more
  • Boston, Massachusetts
  • +19 more
Jul 12, 2021

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer Trial in France, Switzerland, United Kingdom (1.0% IP-001 for

Recruiting
  • Metastatic Solid Tumor
  • +3 more
  • 1.0% IP-001 for Injection
  • Bordeaux, France
  • +9 more
Jan 26, 2023

Carcinoma, Renal Cell, NSCLC Trial in Belgium, France (Live Bacterial Product - Akkermansia muciniphila)

Recruiting
  • Carcinoma, Renal Cell
  • Carcinoma, Non-Small-Cell Lung
  • Live Bacterial Product - Akkermansia muciniphila
  • Mons, Belgium
  • +3 more
May 9, 2023

Neoadjuvant Immunotherapy in Advanced NSCLC

Not yet recruiting
  • Lung Cancer, Non-small Cell
  • Immunotherapy
  • San Francisco, California
    Power Life Sciences
Jan 21, 2022

Solid Tumor, Adult Trial in Kansas City, Providence (DF9001, Nivolumab)

Not yet recruiting
  • Solid Tumor, Adult
  • Kansas City, Missouri
  • +1 more
Oct 24, 2022

Metastatic NSCLC Trial in Worldwide (Pembrolizumab, Lenvatinib, Docetaxel)

Active, not recruiting
  • Metastatic Non-Small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Bakersfield, California
  • +142 more
Sep 1, 2022

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Houston (Neoantigen specific TCR-T cell drug product,

Recruiting
  • Gynecologic Cancer
  • +11 more
  • Neoantigen specific TCR-T cell drug product
  • Aldesleukin (IL-2)
  • Houston, Texas
    MD Anderson Cancer Center
Jul 27, 2022

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Metastatic Colorectal Cancer Trial in Sutton (PDR001, bevacizumab, mFOLFOX6)

Terminated
  • Metastatic Colorectal Cancer
  • Sutton, Surrey, United Kingdom
    Novartis Investigative Site
Oct 7, 2021

Locally Advanced/Metastatic Solid Tumors Trial in United States (BJ-001, Pembrolizumab)

Recruiting
  • Locally Advanced/Metastatic Solid Tumors
  • Saint Louis, Missouri
  • +4 more
Jun 5, 2022

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)

Active, not recruiting
  • MSI-H Colorectal Cancer
  • +30 more
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)

Suspended
  • Solid Tumor
  • ARID1A Gene Mutation
  • Greenville, South Carolina
    Prisma Health Cancer Institute
Jan 10, 2023